RxDoctor Payments Data

Emma Rubin, MD

Internal Medicine · Scranton, PANPI 1902965924

Payments from drug & device makers

$7,645in general payments, 2019–2025

Across 535 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • GSK$976
  • AbbVie$812
  • Johnson & Johnson$692
  • Pfizer$472
  • Takeda Pharmaceuticals U.S.A., Inc.$385
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$120%
  • Food & beverage$7,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,645 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,106
Medicare patients
225
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$141,249
OzempicSemaglutide78$88,353
JardianceEmpagliflozin80$87,227
FarxigaDapagliflozin Propanediol79$83,392
MounjaroTirzepatide35$66,158
TradjentaLinagliptin60$52,957
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$51,207
JanuviaSitagliptin Phosphate45$48,289
RybelsusSemaglutide19$26,897
MyrbetriqMirabegron36$23,101
Breo ElliptaFluticasone/Vilanterol35$17,496
LinzessLinaclotide15$13,900
Dexlansoprazole DrDexlansoprazole42$12,828
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$11,535
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$85$147,066153 claims
PfizerEliquis$472$141,249176 claims
Novo NordiskOzempic, Rybelsus$356$115,25197 claims
AstraZenecaFarxiga$197$83,39279 claims
GSKTrelegy Ellipta, Breo Ellipta$976$68,70386 claims
Lilly USA, LLCMounjaro$339$66,15835 claims
MerckJanuvia$62$48,28945 claims
Astellas Pharma US IncMyrbetriq$105$23,10136 claims
AbbVieLinzess, Synthroid$812$16,86259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →